Impact of Formularies on Clinical Innovation

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 17, 2003, Pages 11-14

  Goodwin, Frederick K ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DRUG FORMULARY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH SERVICE; MANAGED CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REIMBURSEMENT; TREATMENT PLANNING;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY; DRUG UTILIZATION; DRUGS, GENERIC; FORMULARIES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MANAGED CARE PROGRAMS; ORGANIZATIONAL INNOVATION; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 0346120206     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Gray BH, Field MJ, eds. Controlling Costs and Changing Patient Care?: The Role of Utilization Management. Committee on Utilization Management by Third Parties, Institute of Medicine. Washington, D.C.: National Academy Press; 1989
2. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-162
3. Serradell J, Galle B. Prescribing for unlabeled indications. HMO Pract 1993;7:44-47
4. Pandolfini C, Impicciatore P, Provasi D, et al. Off-label use of drugs in Italy: a prospective, observational, and multicenter study. Acta Paediatr 2002;91:339-347
5. Brosgart CL, Mitchell T, Charlebois E, et al. Off-label drug use in human immunodificiency virus disease. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:56-62
6. Weiss E, Hummer M, Keller D, et al. Off-label use of antipsychotic drugs. J Clin Psychopharmacol 2000;20:695-698
7. Goodwin FK. The price of progress. In: Harriso DC, Osterweis M, Rubin ER, eds. Preparing for Science in the 21st Century. Washington, D.C.: Association of Academic Health Centers; 1991
8. Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: results from the Managed Care Outcomes Project. Am J Managed Care 1996;2:253-264
9. Centers for Medicare and Medicaid Services, Office of the Actuary. National Health Expenditure Amounts and Average Annual Percent Change by Type of Expenditure; Selected Calendar Years 1980-2012. Available at: http://cms.hhs.gov/statistics/nhe/projections-2002/t2.asp. Accessed Sept 3, 2003
10. Horn SD, Sharkey PD, Phillips-Harris C. Formulary limitations and the elderly: results from the Managed Care Outcomes Project. Am J Managed Care 1998;4:1105-1113
11. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med 2000:715-722
12. Freiman JA, Chalmers TC, Smith H Jr., et al. The importance of beta, the type II error, and sample size in the design and interpretation of the randomized controlled trial: survey of 71 "negative" trials. N Engl J Med 1978:299;690-694
13. Numberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60:574-579